2-Chloro-5,6,7,8-tetrahydro-1,6-naphthyridine hydrochloride

2-Chloro-5,6,7,8-tetrahydro-1,6-naphthyridine hydrochloride CAS: 766545-20-4 MDL: MFCD09835503

Molecular Formula: C₈H₁₀Cl₂N₂

CAS Number:  766545-20-4

Storage:               Store at 2-8 C^o, under dry conditions.

Synonyms:   None found

Uses:     Synthesis building block, Organic Synthesis, 1,6-naphthyridine nitrogen heterocycle,  synthesis, chlorine reactions, amine reactions

2-Chloro-5,6,7,8-tetrahydro-1,6-naphthyridine hydrochloride, is a synthetic fine chemical useful in the synthesis of pharmaceuticals and fine organic chemicals.

Selected Patents and References:

Aebi, J.; Amrein, K.; Chen, W.; Hornsperger, B.; Kuhn, B.; Liu, Y.; Maerki, H. P.; Mayweg, A. V.; Mohr, P.; Tan, X.; Wang, Z.; Zhou, M. New bicyclic dihydroisoquinolin-1-one derivatives as aldosterone synthase inhibitors and their preparation. WO2013079452A1, 2013.

Ashton, W. T.; Caldwell, C. G.; Duffy, J. L.; Mathvink, R. J.; Wang, L.; Weber, A. E. 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes. WO2004069162A2, 2004.

Benbow, J. W. Preparation of substituted 2H-[1,2,4]triazolo[4,3-a]pyrazines as GSK-3 inhibitors. WO2005035532A1, 2005.

Benbow, J. W.; Chu-Moyer, M. Y.; Kung, D. W. Preparation of substituted 4-amino[1,2,4]triazolo[4,3-a]quinoxalines for treating glycogen synthase kinase 3 (GSK-3) mediated conditions. US20040192698A1, 2004.

Blagg, J.; Fray, M. J.; Lewis, M. L.; Mathias, J. P.; Stefaniak, M. H.; Stobie, A. Preparation of alkoxy quinazolinone compounds as α1L adrenoceptors antagonists useful in therapy. WO2003076427A1, 2003.

Buchanan, J. L.; Bregman, H.; Chakka, N.; Dimauro, E. F.; Du, B.; Nguyen, H. N.; Zheng, X. M. Preparation of triazine compounds as inhibitors of voltage-gated sodium channels for treating chronic pain disorders. WO2010022055A2, 2010.

Chen, L.; Yang, Y.; Liu, L.; Gao, Q.; Xu, S., Iridium-Catalyzed Enantioselective α-C(sp3)-H Borylation of Azacycles. J. Am. Chem. Soc. 2020, 142 (28), 12062-12068.

Fox, D. N. A. Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia. WO9830560A1, 1998

Li, Z.; Wang, X.; Eksterowicz, J.; Gribble, M. W.; Alba, G. Q.; Ayres, M.; Carlson, T. J.; Chen, A.; Chen, X.; Cho, R.; Connors, R. V.; DeGraffenreid, M.; Deignan, J. T.; Duquette, J.; Fan, P.; Fisher, B.; Fu, J.; Huard, J. N.; Kaizerman, J.; Keegan, K. S.; Li, C.; Li, K.; Li, Y.; Liang, L.; Liu, W.; Lively, S. E.; Lo, M.-C.; Ma, J.; McMinn, D. L.; Mihalic, J. T.; Modi, K.; Ngo, R.; Pattabiraman, K.; Piper, D. E.; Queva, C.; Ragains, M. L.; Suchomel, J.; Thibault, S.; Walker, N.; Wang, X.; Wang, Z.; Wanska, M.; Wehn, P. M.; Weidner, M. F.; Zhang, A. J.; Zhao, X.; Kamb, A.; Wickramasinghe, D.; Dai, K.; McGee, L. R.; Medina, J. C., Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3. J. Med. Chem. 2014, 57 (8), 3430-3449.

Orwat, M. J.; Pinto, D. J. P.; Smith, L. M., II; Srivastava, S.; Corte, J. R. Preparation of substituted tetrahydroisoquinoline compounds as factor XIa inhibitors. WO2013055984A1, 2013.